Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: Implications for clinical therapies

Brain Research

Volumn 854, Issue 1-2, 2000, Pages 35-41

  Freo, Ulderico ^a   Ori, Carlo ^a   Dam, Mauro ^a   Merico, Antonio ^a   Pizzolato, Gilberto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Fluoxetine; Rat; Regional cerebral metabolic rate for glucose; Serotonin; Serotonin reuptake inhibitor; Stress

Indexed keywords

DEOXYGLUCOSE; FLUOXETINE; GLUCOSE; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; FLUOXETINE; GLUCOSE; MALE; RATS; RATS, INBRED F344; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0033980031     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02261-1     Document Type: Article

References (46)

1. Abene M.V., Hamilton J.D. Resolution of fear of flying with fluoxetine treatment. Anxiety Disord. 12:1998;599-603.
2. H.A. Akil, M.I. Morano, Stress, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology, The Fourth Generation of Progress, Raven Press, New York, USA, 1994, pp. 773-786.
3. 3H ]paroxetine as an in vivo ligand for serotonin uptake sites: quantitative autoradiographic study in the rat brain Synapse. 13:1993;1-9.
4. Baker A., Herkenham M., Brady L.S. Effects of long-term treatment with antidepressant drugs on proopiomelanocortin and neuropeptide Y mRNA expression in the hypothalamic arcuate nucleus of rats. J. Neuroendocrinol. 8:1996;337-343.
5. Batki S.L., Washburn A.M., Delucchi K., Jones R.T. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend. 41:1996;137-142.
6. Baxter L. Positron emission tomography studies of cerebral glucose metabolism in obsessive compulsive disorders. J. Clin. Psychiatry. 55S:1994;54-59.
7. Brady L.S., Gold P.W., Herkenham M., Lynn A.B., Whitfield H.J. Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 572:1992;117-125.
8. Caccia S., Anelli M., Codegoni A.M., Fracasso C., Garattini S. The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain. Br. J. Pharmacol. 110:1993;355-359.
9. Caccia S., Bizzi A., Coltro G., Fracasso C., Frittoli E., Mennini T., Garattini S. Anorectic activity of fluoxetine and norfluoxetine in rats: relationship between brain concentrations and in vitro potencies on monoaminergic mechanisms. J. Pharm. Pharmacol. 44:1992;250-254.
10. Chaput C., de Montigny C., Blier P. Presynaptic and postsynaptic modification of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiological study in rat. Neuropsychopharmacology. 5:1991;219-229.
11. Chiu T.H., Yang Y.R., Yang J.J., Chen C.L. Inhibition of locus coeruleus neurons by serotonin at high doses. Chin. J. Physiol. 38:1995;153-157.
12. Cook E.H. Jr., Metz J., Leventhal B.L., Lebovits M., Nathan M., Semerdjian S.A., Brown T., Cooper M.D. Fluoxetine effects on cerebral glucose metabolism. NeuroReport. 5:1994;1745-1748.
13. Curtis A.L., Valentino R.J. Corticotropin-releasing factor neurotransmission in the locus coeruleus: a possible site of antidepressant action. Brain Res. Bull. 35:1994;581-587.
14. Dam M., Tonin P., De Boni A., Pizzolato G., Casson S., Ermani M., Freo U., Piron L., Battistin L. The effects of fluoxetine and maprotiline on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 27:1996;1211-1214.
15. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Aghajanian G.K., Heninger G.R., Charney D.S. Serotonin and the neurobiology of depression. Arch. Gen. Psychiatry. 51:1994;865-874.
16. DeLong G.R., Teague L.A., McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev. Med. Child Neurol. 40:1998;551-562.
17. Favale E., Rubino V., Mainardi P., Lunardi G., Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology. 45:1995;1926-1927.
18. Freo U. Cerebral metabolic effects of serotonin drugs and neurotoxins. A minireview. Life Sci. 59:1996;877-891.
19. Freo U., Larson D.M., Soncrant T.T. Cerebral metabolic responses to metachlorophenylpiperazine are reduced during its chronic administration to young and aged rats. Gerontology. 39:1993;305-313.
20. Freo U., Pietrini P., Pizzolato G., Furey M., Merico A., Ruggero S., Dam M., Battistin L. Cerebral metabolic responses to clomipramine are greatly reduced following pretreatment with the specific serotonin neurotoxin parachloramphetamine (PCA). A 2-deoxyglucose study in rats. Neuropsychopharmacology. 13:1995;215-222.
21. Frey J., Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology. 44:1994;707-709.
22. Gardier A.H., Lepoul E., Trouvin J.H., Chanut E., Dessalles M.C., Jacquot C. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci. 54:1993;51-56.
23. Gatch M.B., Negus S.S., Mello N.K. Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu-opioid agonists in rhesus monkeys. Psychopharmacology. 1:1998;99-106.
24. J.C. Gerber III, J. Choki, D.J. Brunswick, M. Reivich, A. Frazer, The effect of antidepressant drugs on regional cerebral glucose utilization in the rat, Brain Res. (1983) 319-325.
25. 2 receptors: involvement of the prepositus hypoglossal nucleus. Neuropharmacology. 30:1991;1309-1318.
26. Haddjeri N., de Montigny C., Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydrotryptamine system. Br. J. Pharmacol. 120:1997;865-875.
27. Holladay J.W., Dewey M.J., Yoo S.D. Kinetic interaction between fluoxetine and imipramine as a function of elevated serum alpha-1-acid glycoprotein levels. J. Pharm. Pharmacol. 50:1998;419-424.
28. Kornreich C., Dan B., Verbanck P., Fontaine E., Pelc I. Divergent responses to fluoxetine from two compulsive, food-related conditions: bulimia nervosa and compulsive water drinking. Biol. Psychiatry. 43:1998;310-311.
29. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274:1995;866-887.
30. Lejoyeux M. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol Alcohol. Suppl. 1:1996;69-75.
31. Lesch K.P., Aulakh C.S., Wolozin B.L., Tolliver T.J., Hill J.L., Murphy D.L. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol. Brain Res. 17:1993;31-35.
32. M. Maes, H.Y. Meltzer, The serotonin hypothesis of major depression, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology. The Fourth Generation of Progress, Raven Press, New York, USA, pp. 933-944.
33. Mann J.J., Malone K.M., Diehl D.J., Perel J., Cooper T.B., Mintun M. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am. J. Psychiatry. 153:1996;174-182.
34. McRae-Deguerurce A., Dennis T., Leger L., Scatton B. Regulation of neuronal activity in the rat locus coeruleus by serotoninergic afferents. Physiol. Psychol. 13:1985;188-196.
35. Nestler E.J., McMahon A., Sabban E.L., Tallman J.F., Duman R.S. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc. Natl. Acad. Sci. U.S.A. 87:1990;7522-7526.
36. 1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology. 15:1996;515-522.
37. Pineyro G., Blier P., Dennis T., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J. Neurosci. 14:1994;3036-3047.
38. Porrino L., Muller M., Hedgecock A.A., Thornly C., Matasi J.J., Davies H.W.M.L. Local cerebral metabolic effects of the novel cocaine analog, WF-31: comparisons to fluoxetine. Synapse. 27:1997;26-35.
39. Prisco S., Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Br. J. Pharmacol. 116:1995;1923-1931.
40. Pucilowski O., Overstreet D.H. Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Brain Res. Bull. 32:1993;471-475.
41. Renshaw P.F., Guimaraes A.R., Fava M., Rosenbaum J.F., Pearlman J.D., Flood J.G., Puopolo P.R., Clancy K., Gonzales G. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am. J. Psychiatry. 149:1992;1592-1594.
42. 14C ]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal value in the conscious and anesthetized albino rat J. Neurochem. 28:1985;897-916.
43. T.T. Soncrant, G. Pizzolato, L. Battistin, The use of drugs as probes of cerebral function, In: L. Battistin, F. Gerstenbrand (Eds.), PET and NMR: New Perspectives in Neuroimaging and in Clinical Neurochemistry, Liss, New York, 1985, pp. 131-149.
44. Steiner M., Korzekwa M., Lamont J., Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol. Bull. 33:1997;771-774.
45. Tanda G., Frau R., Di Chiara G. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in rat prefrontal cortex. Psychopharmacology. 127:1996;83-87.
46. Tulloch I.F. The pharmacology of selective serotonin reuptake inhibitors. Eur. J. Psychopharmacol. 8:1993;5-8.